Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Oligodendrocyte Progenitor Cells in the Tumor Microenvironment.

Hide T, Komohara Y.

Adv Exp Med Biol. 2020;1234:107-122. doi: 10.1007/978-3-030-37184-5_8. Review.

PMID:
32040858
2.

[A Case of Familial Schwannomatosis Occurring as Intraorbital Schwannoma].

Miyasaka K, Shibahara I, Hide T, Inukai M, Saegusa M, Nakano Y, Ichimura K, Takaso M, Kumabe T.

No Shinkei Geka. 2020 Jan;48(1):71-77. doi: 10.11477/mf.1436204137. Japanese.

PMID:
31983691
3.

Case of Calcifying Pseudoneoplasms of the Neuraxis Coexisting with Interhemispheric Lipoma and Agenesis of the Corpus Callosum: Involvement of Infiltrating Macrophages.

Inukai M, Shibahara I, Hotta M, Miyasaka K, Sato S, Hide T, Saegusa M, Kumabe T.

World Neurosurg. 2020 Feb;134:635-640.e1. doi: 10.1016/j.wneu.2019.10.182. Epub 2019 Nov 5.

PMID:
31704362
4.

Temporal Glioblastoma Mimicking Basal Ganglia Invasion: Distinguishing Removable and Unremovable Tumors.

Shibahara I, Hanihara M, Miyasaka K, Sato S, Hide T, Kumabe T.

World Neurosurg. 2019 Oct;130:e213-e221. doi: 10.1016/j.wneu.2019.06.035. Epub 2019 Jun 25.

PMID:
31252080
5.

Novel concept of the border niche: glioblastoma cells use oligodendrocytes progenitor cells (GAOs) and microglia to acquire stem cell-like features.

Hide T, Shibahara I, Kumabe T.

Brain Tumor Pathol. 2019 Apr;36(2):63-73. doi: 10.1007/s10014-019-00341-2. Epub 2019 Apr 9. Review.

PMID:
30968276
6.

New Radiologic Findings of Hypertrophic Olivary Degeneration in 2 Patients with Brainstem Lymphoma.

Sato S, Shibahara I, Inoue Y, Hide T, Kumabe T.

World Neurosurg. 2019 Mar;123:464-468.e1. doi: 10.1016/j.wneu.2018.11.161. Epub 2018 Nov 26.

PMID:
30496930
7.

Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border.

Hide T, Komohara Y, Miyasato Y, Nakamura H, Makino K, Takeya M, Kuratsu JI, Mukasa A, Yano S.

EBioMedicine. 2018 Apr;30:94-104. doi: 10.1016/j.ebiom.2018.02.024. Epub 2018 Mar 1.

8.

Usefulness of Oblique Coronal Computed Tomography and Magnetic Resonance Imaging in the Endoscopic Endonasal Approach to Treat Skull Base Lesions.

Yano S, Shinojima N, Kitajima M, Uetani H, Hide T, Mukasa A.

World Neurosurg. 2018 May;113:e10-e19. doi: 10.1016/j.wneu.2018.01.022. Epub 2018 Jan 8.

PMID:
29325947
9.

Endoscopic endonasal transsphenoidal surgery for patients aged over 80 years with pituitary adenomas: Surgical and follow-up results.

Fujimoto K, Yano S, Shinojima N, Hide T, Kuratsu JI.

Surg Neurol Int. 2017 Sep 6;8:213. doi: 10.4103/sni.sni_189_17. eCollection 2017.

10.

In Reply to "Craniopharyngioma: Surgical Outcome as Related to the Degree of Hypothalamic Involvement".

Yano S, Hide T, Shinojima N.

World Neurosurg. 2017 Aug;104:1011-1013. doi: 10.1016/j.wneu.2017.03.040. No abstract available.

PMID:
28732411
11.

Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma.

Takahashi Y, Sawada T, Akahane T, Kawase Y, Ikeda H, Makino K, Nakamura H, Hide T, Yano S, Hashimoto N, Kamada H.

Oncol Lett. 2017 Jul;14(1):264-270. doi: 10.3892/ol.2017.6122. Epub 2017 May 4.

12.

Intraoperative Scoring System to Predict Postoperative Remission in Endoscopic Endonasal Transsphenoidal Surgery for Growth Hormone-Secreting Pituitary Adenomas.

Yano S, Shinojima N, Kawashima J, Kondo T, Hide T.

World Neurosurg. 2017 Sep;105:375-385. doi: 10.1016/j.wneu.2017.05.162. Epub 2017 Jun 27.

PMID:
28602880
13.

Surgical Outcomes of Endoscopic Endonasal Skull Base Surgery of Craniopharyngiomas Evaluated According to the Degree of Hypothalamic Extension.

Yano S, Hide T, Shinojima N.

World Neurosurg. 2017 Apr;100:288-296. doi: 10.1016/j.wneu.2017.01.005. Epub 2017 Jan 12.

PMID:
28089805
14.

Efficacy and Complications of Endoscopic Skull Base Surgery for Giant Pituitary Adenomas.

Yano S, Hide T, Shinojima N.

World Neurosurg. 2017 Mar;99:533-542. doi: 10.1016/j.wneu.2016.12.068. Epub 2016 Dec 23.

PMID:
28024972
15.

Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.

Yano S, Hide T, Uekawa K, Honda Y, Mikami Y, Kuratsu JI.

World Neurosurg. 2016 Nov;95:620.e17-620.e22. doi: 10.1016/j.wneu.2016.08.011. Epub 2016 Aug 13.

PMID:
27535625
16.

Quality of Life and Clinical Features of Long-Term Survivors Surgically Treated for Pediatric Craniopharyngioma.

Yano S, Kudo M, Hide T, Shinojima N, Makino K, Nakamura H, Kuratsu J.

World Neurosurg. 2016 Jan;85:153-62. doi: 10.1016/j.wneu.2015.08.059. Epub 2015 Sep 1.

PMID:
26341425
17.

Novel metal chelating molecules with anticancer activity. Striking effect of the imidazole substitution of the histidine-pyridine-histidine system.

Ali TF, Iwamaru K, Ciftci HI, Koga R, Matsumoto M, Oba Y, Kurosaki H, Fujita M, Okamoto Y, Umezawa K, Nakao M, Hide T, Makino K, Kuratsu J, Abdel-Aziz M, Abuo-Rahma Gel-D, Beshr EA, Otsuka M.

Bioorg Med Chem. 2015 Sep 1;23(17):5476-82. doi: 10.1016/j.bmc.2015.07.044. Epub 2015 Jul 29.

PMID:
26260338
18.

Ceacam1L Modulates STAT3 Signaling to Control the Proliferation of Glioblastoma-Initiating Cells.

Kaneko S, Nakatani Y, Takezaki T, Hide T, Yamashita D, Ohtsu N, Ohnishi T, Terasaka S, Houkin K, Kondo T.

Cancer Res. 2015 Oct 1;75(19):4224-34. doi: 10.1158/0008-5472.CAN-15-0412. Epub 2015 Aug 3.

19.

[Brain tumor stem cells].

Hide T, Makino K, Nakamura H, Yano S, Kuratsu J.

Nihon Rinsho. 2015 May;73(5):836-43. Japanese.

PMID:
25985640
20.

A flexible endoscope-assisted interhemispheric transcallosal approach through the contralateral ventricle for the removal of a third ventricle craniopharyngioma: A technical report.

Yano S, Hide T, Shinojima N, Ueda Y, Kuratsu J.

Surg Neurol Int. 2015 Mar 19;6(Suppl 2):S113-6. doi: 10.4103/2152-7806.153653. eCollection 2015.

21.

Usefulness of the indocyanine green fluorescence endoscope in endonasal transsphenoidal surgery.

Hide T, Yano S, Shinojima N, Kuratsu J.

J Neurosurg. 2015 May;122(5):1185-92. doi: 10.3171/2014.9.JNS14599. Epub 2015 Feb 27.

PMID:
25723307
22.
23.

Characteristics of brain metastases from esophageal carcinoma.

Yamamoto T, Kuroda J, Takezaki T, Shinojima N, Hide T, Makino K, Nakamura H, Yano S, Nishi T, Kuratsu J.

Surg Neurol Int. 2014 Sep 22;5:137. doi: 10.4103/2152-7806.141468. eCollection 2014.

24.

Clinical characteristics and pathogenesis of cerebellar glioblastoma.

Takahashi Y, Makino K, Nakamura H, Hide T, Yano S, Kamada H, Kuratsu J.

Mol Med Rep. 2014 Nov;10(5):2383-8. doi: 10.3892/mmr.2014.2549. Epub 2014 Sep 9.

PMID:
25199771
25.

Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.

Guo J, Shinriki S, Su Y, Nakamura T, Hayashi M, Tsuda Y, Murakami Y, Tasaki M, Hide T, Takezaki T, Kuratsu J, Yamashita S, Ueda M, Li JD, Ando Y, Jono H.

Oncotarget. 2014 Aug 15;5(15):6353-64.

26.

Endoscopic endonasal skull base approach for parasellar lesions: Initial experiences, results, efficacy, and complications.

Yano S, Hide T, Shinojima N, Hasegawa Y, Kawano T, Kuratsu J.

Surg Neurol Int. 2014 Apr 16;5:51. doi: 10.4103/2152-7806.130901. eCollection 2014.

27.

Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.

Makino K, Nakamura H, Hide T, Kuroda J, Yano S, Kuratsu J.

Int J Clin Oncol. 2015 Feb;20(1):29-34. doi: 10.1007/s10147-014-0692-4. Epub 2014 Apr 11.

PMID:
24722885
28.

Antitumor effect of fibrin glue containing temozolomide against malignant glioma.

Anai S, Hide T, Takezaki T, Kuroda J, Shinojima N, Makino K, Nakamura H, Yano S, Kuratsu J.

Cancer Sci. 2014 May;105(5):583-91. doi: 10.1111/cas.12397. Epub 2014 Apr 19.

29.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

30.

New treatment strategies to eradicate cancer stem cells and niches in glioblastoma.

Hide T, Makino K, Nakamura H, Yano S, Anai S, Takezaki T, Kuroda J, Shinojima N, Ueda Y, Kuratsu J.

Neurol Med Chir (Tokyo). 2013;53(11):764-72. Epub 2013 Oct 21. Review.

31.

Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.

Niibori-Nambu A, Midorikawa U, Mizuguchi S, Hide T, Nagai M, Komohara Y, Nagayama M, Hirayama M, Kobayashi D, Tsubota N, Takezaki T, Makino K, Nakamura H, Takeya M, Kuratsu J, Araki N.

PLoS One. 2013 May 21;8(5):e59558. doi: 10.1371/journal.pone.0059558. Print 2013.

32.

A case of ecchordosis physaliphora presenting with an abducens nerve palsy: A rare symptomatic case managed with endoscopic endonasal transsphenoidal surgery.

Yamamoto T, Yano S, Hide T, Kuratsu J.

Surg Neurol Int. 2013;4:13. doi: 10.4103/2152-7806.106562. Epub 2013 Jan 28.

33.

Giant tumefactive perivascular spaces that expanded and became symptomatic 14 years after initial surgery.

Fujimoto K, Kuroda J, Hide T, Hasegawa Y, Yano S, Kuratsu J.

Surg Neurol Int. 2012;3:127. doi: 10.4103/2152-7806.102942. Epub 2012 Oct 27.

34.

Higher incidence of epilepsy in meningiomas located on the premotor cortex: a voxel-wise statistical analysis.

Hamasaki T, Yamada K, Yano S, Nakamura H, Makino K, Hide T, Hasegawa Y, Kuroda J, Hirai T, Kuratsu J.

Acta Neurochir (Wien). 2012 Dec;154(12):2241-9. doi: 10.1007/s00701-012-1511-1. Epub 2012 Oct 21.

PMID:
23086105
35.

Usefulness of immunohistochemical expression analysis of metabolic-related molecules in differentiating between intracranial neoplastic and non-neoplastic lesions.

Makino K, Nakamura H, Hide T, Yano S, Kuroda J, Takahashi Y, Iyama K, Kuratsu J.

Brain Tumor Pathol. 2013 Jul;30(3):144-50. doi: 10.1007/s10014-012-0120-2. Epub 2012 Oct 12.

PMID:
23064941
36.

Induction of autophagic cell death of glioma-initiating cells by cell-penetrating D-isomer peptides consisting of Pas and the p53 C-terminus.

Ueda Y, Wei FY, Hide T, Michiue H, Takayama K, Kaitsuka T, Nakamura H, Makino K, Kuratsu J, Futaki S, Tomizawa K.

Biomaterials. 2012 Dec;33(35):9061-9. doi: 10.1016/j.biomaterials.2012.09.003. Epub 2012 Sep 21.

PMID:
23006589
37.

Pituitary apoplexy associated with endocrine stimulation test: endocrine stimulation test, treatment, and outcome.

Yamamoto T, Yano S, Kuroda J, Hasegawa Y, Hide T, Kuratsu J.

Case Rep Endocrinol. 2012;2012:826901. doi: 10.1155/2012/826901. Epub 2012 Aug 15.

38.

Fatty acid synthase is a predictive marker for aggressiveness in meningiomas.

Makino K, Nakamura H, Hide T, Yano S, Kuroda J, Iyama K, Kuratsu J.

J Neurooncol. 2012 Sep;109(2):399-404. doi: 10.1007/s11060-012-0907-3. Epub 2012 Jun 29.

PMID:
22744755
39.

Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.

Makino K, Nakamura H, Hide T, Kuratsu J.

J Neurooncol. 2012 Jan;106(1):155-60. doi: 10.1007/s11060-011-0652-z. Epub 2011 Jul 1.

PMID:
21720808
40.

Essential role of the Hedgehog signaling pathway in human glioma-initiating cells.

Takezaki T, Hide T, Takanaga H, Nakamura H, Kuratsu J, Kondo T.

Cancer Sci. 2011 Jul;102(7):1306-12. doi: 10.1111/j.1349-7006.2011.01943.x. Epub 2011 May 3.

41.
42.

Risk of primary childhood brain tumors related to season of birth in Kumamoto Prefecture, Japan.

Makino K, Nakamura H, Hide T, Kuratsu J; Kumamoto Brain Tumor Group.

Childs Nerv Syst. 2011 Jan;27(1):75-8. doi: 10.1007/s00381-010-1235-6. Epub 2010 Jul 22.

PMID:
20652260
43.

Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation.

Hide T, Takezaki T, Nakatani Y, Nakamura H, Kuratsu J, Kondo T.

Cancer Res. 2009 Oct 15;69(20):7953-9. doi: 10.1158/0008-5472.CAN-09-2006. Epub 2009 Oct 6.

44.

[Progress in the study of brain tumor stem cells as treatment targets].

Hide T, Kuratsu J.

Brain Nerve. 2009 Jul;61(7):781-9. Review. Japanese.

PMID:
19618855
45.

Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation.

Kudo M, Jono H, Shinriki S, Yano S, Nakamura H, Makino K, Hide T, Muta D, Ueda M, Ota K, Ando Y, Kuratsu J.

J Neurosurg. 2009 Aug;111(2):219-25. doi: 10.3171/2008.12.JNS081284.

PMID:
19326989
46.

Brain tumor stem cells as research and treatment targets.

Hide T, Takezaki T, Nakamura H, Kuratsu J, Kondo T.

Brain Tumor Pathol. 2008;25(2):67-72. doi: 10.1007/s10014-008-0237-5. Epub 2008 Nov 6. Review.

PMID:
18987831
47.

Identification of human brain tumour initiating cells.

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB.

Nature. 2004 Nov 18;432(7015):396-401.

48.

Cancer stem cells in nervous system tumors.

Singh SK, Clarke ID, Hide T, Dirks PB.

Oncogene. 2004 Sep 20;23(43):7267-73. Review.

PMID:
15378086
49.

eVOC: a controlled vocabulary for unifying gene expression data.

Kelso J, Visagie J, Theiler G, Christoffels A, Bardien S, Smedley D, Otgaar D, Greyling G, Jongeneel CV, McCarthy MI, Hide T, Hide W.

Genome Res. 2003 Jun;13(6A):1222-30.

50.

Genetic modifiers of otocephalic phenotypes in Otx2 heterozygous mutant mice.

Hide T, Hatakeyama J, Kimura-Yoshida C, Tian E, Takeda N, Ushio Y, Shiroishi T, Aizawa S, Matsuo I.

Development. 2002 Sep;129(18):4347-57.

Supplemental Content

Support Center